Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

AstraZeneca (AZN) Receives a Buy from Goldman Sachs

Tipranks - Tipranks - Sat Apr 4, 12:02PM CDT

In a report released yesterday, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca, with a price target of p16,600.00. The company’s shares closed yesterday at p15,316.00.

End of Quarter Sale - 50% Off TipRanks

According to TipRanks, Sharma is a 2-star analyst with an average return of 0.7% and a 50.53% success rate. Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, Immunocore Holdings, and Valneva.

In addition to Goldman Sachs, AstraZeneca also received a Buy from Bank of America Securities’s Sachin Jain in a report issued on April 1. However, on March 30, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).

See the top stocks recommended by analysts >>

Based on AstraZeneca’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p15.5 billion and a net profit of p2.33 billion. In comparison, last year the company earned a revenue of p14.54 billion and had a net profit of p1.46 billion

Read More on GB:AZN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).